A pivotal decade for bispecific antibodies?
Bispecific antibodies (bsAbs) are a class of antibodies that can mediate novel mechanisms of action compared to monospecific monoclonal antibodies (mAbs). Since the discovery of mAbs and their adoption as therapeutic agents in the 1980s and 1990s, the development of bsAbs has held substantial appeal...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2321635 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576589001392128 |
|---|---|
| author | Marlena Surowka Christian Klein |
| author_facet | Marlena Surowka Christian Klein |
| author_sort | Marlena Surowka |
| collection | DOAJ |
| description | Bispecific antibodies (bsAbs) are a class of antibodies that can mediate novel mechanisms of action compared to monospecific monoclonal antibodies (mAbs). Since the discovery of mAbs and their adoption as therapeutic agents in the 1980s and 1990s, the development of bsAbs has held substantial appeal. Nevertheless, only three bsAbs (catumaxomab, blinatumomab, emicizumab) were approved through the end of 2020. However, since then, 11 bsAbs received regulatory agency approvals, of which nine (amivantamab, tebentafusp, mosunetuzumab, cadonilimab, teclistamab, glofitamab, epcoritamab, talquetamab, elranatamab) were approved for the treatment of cancer and two (faricimab, ozoralizumab) in non-oncology indications. Notably, of the 13 currently approved bsAbs, two, emicizumab and faricimab, have achieved blockbuster status, showing the promise of this novel class of therapeutics. In the 2020s, the approval of additional bsAbs can be expected in hematological malignancies, solid tumors and non-oncology indications, establishing bsAbs as essential part of the therapeutic armamentarium. |
| format | Article |
| id | doaj-art-f56b39943c694d6697f67b9d846bd8d7 |
| institution | Kabale University |
| issn | 1942-0862 1942-0870 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | mAbs |
| spelling | doaj-art-f56b39943c694d6697f67b9d846bd8d72025-01-31T04:19:38ZengTaylor & Francis GroupmAbs1942-08621942-08702024-12-0116110.1080/19420862.2024.2321635A pivotal decade for bispecific antibodies?Marlena Surowka0Christian Klein1Roche Innovation Center Zurich, Roche Pharma Research & Early Development, Roche Glycart AG, Schlieren, SwitzerlandRoche Innovation Center Zurich, Roche Pharma Research & Early Development, Roche Glycart AG, Schlieren, SwitzerlandBispecific antibodies (bsAbs) are a class of antibodies that can mediate novel mechanisms of action compared to monospecific monoclonal antibodies (mAbs). Since the discovery of mAbs and their adoption as therapeutic agents in the 1980s and 1990s, the development of bsAbs has held substantial appeal. Nevertheless, only three bsAbs (catumaxomab, blinatumomab, emicizumab) were approved through the end of 2020. However, since then, 11 bsAbs received regulatory agency approvals, of which nine (amivantamab, tebentafusp, mosunetuzumab, cadonilimab, teclistamab, glofitamab, epcoritamab, talquetamab, elranatamab) were approved for the treatment of cancer and two (faricimab, ozoralizumab) in non-oncology indications. Notably, of the 13 currently approved bsAbs, two, emicizumab and faricimab, have achieved blockbuster status, showing the promise of this novel class of therapeutics. In the 2020s, the approval of additional bsAbs can be expected in hematological malignancies, solid tumors and non-oncology indications, establishing bsAbs as essential part of the therapeutic armamentarium.https://www.tandfonline.com/doi/10.1080/19420862.2024.2321635bsAbbsADCCD3εCPIIgGmab |
| spellingShingle | Marlena Surowka Christian Klein A pivotal decade for bispecific antibodies? mAbs bsAb bsADC CD3ε CPI IgG mab |
| title | A pivotal decade for bispecific antibodies? |
| title_full | A pivotal decade for bispecific antibodies? |
| title_fullStr | A pivotal decade for bispecific antibodies? |
| title_full_unstemmed | A pivotal decade for bispecific antibodies? |
| title_short | A pivotal decade for bispecific antibodies? |
| title_sort | pivotal decade for bispecific antibodies |
| topic | bsAb bsADC CD3ε CPI IgG mab |
| url | https://www.tandfonline.com/doi/10.1080/19420862.2024.2321635 |
| work_keys_str_mv | AT marlenasurowka apivotaldecadeforbispecificantibodies AT christianklein apivotaldecadeforbispecificantibodies AT marlenasurowka pivotaldecadeforbispecificantibodies AT christianklein pivotaldecadeforbispecificantibodies |